Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIJ821 for rapid reduction of depressive symptoms in suicidal major depressive disorder
jRCT2031210369Completed
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of onfasprodil in major depressive disorder (MDD) and suicidal ideation (7 arms), sponsored by Novartis. Primary endpoint: Change from baseline in MADRS total score at 24 hours. Started Dec 2021; status: completed.
02
Drugs
onfasprodil
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on jRCT2031210369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210369.